All In Biotech

NDA 217628 · Carwin Pharm Assoc

Clotic

Clotrimazole · Otic · Azole Antifungal

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 26, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 11 recruiting

FAERS reports

11,719

9,076 serious, 937 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

CLOTIC is indicated for the treatment of fungal otitis externa (otomycosis) due to Aspergillus species and Candida species in patients 18 years of age and older. Limitations of Use CLOTIC has only been studied in patients with intact tympanic membranes. The use of CLOTIC is not recommended for the treatment of otomycosis in patients with perforated tympanic membranes. CLOTIC is an azole antifungal indicated for the treatment of fungal otitis externa (otomycosis) due to Aspergillus species and Candida species in patients 18 years of age and older. ( 1 ) Limitations of Use CLOTIC has only been studied in patients with intact tympanic membranes. The use of CLOTIC is not recommended for the treatment of otomycosis in patients with perforated tympanic membranes

Mechanism: Clotrimazole is an azole antifungal agent [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 26, 2025 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetter
1 products under this application
  • CLOTIC · CLOTRIMAZOLE 1% · SOLUTION/DROPS, OTIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clotrimazole" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,384
  • nausea825
  • macular degeneration812
  • pain782
  • off label use769
  • headache754
  • dyspnoea726
  • fatigue660
  • diarrhoea618
  • pyrexia528
  • malaise483
  • rash478

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200484
2005114
2006135
2007113
2008122
2009149
2010169
2011229
2012342
2013215
2014296
2015452
2016629
2017588
2018786
2019961
2020863
2021993
2022931
2023893
20241,008
20251,037
2026609

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 342 on PubMed

Sponsor: Carwin Pharm Assoc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.